Story perspectives

Engineered Adenovirus Halts Pancreatic Tumors in Early Trial

5/30/2026

Summary

Story summary

A U.S. trial reported that an engineered adenovirus halted pancreatic tumor growth in three patients.
Researcher Masato Yamamoto’s team injected the virus into each tumor via an ultrasound-guided tube through throat, leaving participants alive with disease.
Researchers will treat 15 patients with higher doses to find the optimal level.
Investigators call the findings hypothesis-generating because the trial lacks a control group and plan to pair the virus with checkpoint-inhibitor immunotherapies.

1 of 1

Story summary

A U.S. trial reported that an engineered adenovirus halted pancreatic tumor growth in three patients.
Researcher Masato Yamamoto’s team injected the virus into each tumor via an ultrasound-guided tube through throat, leaving participants alive with disease.
Researchers will treat 15 patients with higher doses to find the optimal level.
Investigators call the findings hypothesis-generating because the trial lacks a control group and plan to pair the virus with checkpoint-inhibitor immunotherapies.